Patents by Inventor Rajgopal Munigeti

Rajgopal Munigeti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220162177
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Application
    Filed: November 30, 2021
    Publication date: May 26, 2022
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Patent number: 11225467
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: January 18, 2022
    Assignee: PHARMATROPHIX, INC.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Patent number: 10532988
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: January 14, 2020
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Publication number: 20190263763
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Application
    Filed: February 26, 2019
    Publication date: August 29, 2019
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Patent number: 10273219
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 30, 2019
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Publication number: 20180037559
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Application
    Filed: August 21, 2017
    Publication date: February 8, 2018
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Publication number: 20180037560
    Abstract: The present invention includes crystalline forms of (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and salts thereof. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic uses of the crystalline forms.
    Type: Application
    Filed: August 25, 2017
    Publication date: February 8, 2018
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Patent number: 9884833
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide disulfate and crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide monosulfate. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms. In one embodiment, the crystalline compound is (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: February 6, 2018
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Publication number: 20170158653
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide disulfate and crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide monosulfate. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms. In one embodiment, the crystalline compound is (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide.
    Type: Application
    Filed: September 13, 2016
    Publication date: June 8, 2017
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Publication number: 20160176832
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Patent number: 9271986
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 1, 2016
    Assignee: PharmatrophiX, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo
  • Publication number: 20150259278
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide disulfate and crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide monosulfate. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms. In one embodiment, the crystal-line compound is (2S,3S)-2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 17, 2015
    Inventor: Rajgopal Munigeti
  • Publication number: 20130005731
    Abstract: The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide and crystalline forms of salts and/or solvates of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide. Furthermore, the present invention provides compositions comprising the crystalline forms and therapeutic use of the crystalline forms.
    Type: Application
    Filed: November 12, 2010
    Publication date: January 3, 2013
    Applicant: Pharmatrophix, Inc.
    Inventors: Rajgopal Munigeti, Frank M. Longo